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Available online 22 January 2016Phosphodiesterases 4 (PDE4) act as proinﬂammatory enzymes via degradation of cAMP, whereas PDE4 in-
hibitors play an anti-inﬂammatory role in vitro and in vivo. In particular, apremilast has been recently ap-
proved for the treatment of psoriasis and psoriatic arthritis. However, little is known on the expression
pattern of PDE4 in psoriasis. We report that PDE4B and PDE4D mRNA are overexpressed in peripheral
blood mononuclear cells (PBMC) from psoriasis, as compared with normal controls, while apremilast re-
duces PBMC production of a number of pro-inﬂammatory cytokines and increases the levels of anti-
inﬂammatory mediators. PDE4 expression is up-regulated in psoriatic dermis as compared with normal
skin, with particular regard to ﬁbroblasts. This is conﬁrmed in vitro, where both dermal ﬁbroblasts (DF)
and, to a greater extent, myoﬁbroblasts (DM) express all PDE4 isoforms at the mRNA and protein level. Be-
cause PDE4 interacts with the nerve growth factor (NGF) receptor CD271 in lung ﬁbroblasts, we evaluated
the relationship and function of PDE4 and CD271 in normal human skin ﬁbroblasts. All PDE4 isoforms co-
immunoprecipitate with CD271 in DM, while apremilast inhibits apoptosis induced by β-amyloid, a
CD271 ligand, in DM. Furthermore, apremilast signiﬁcantly reduces NGF- and transforming growth
factor-β1 (TGF-β1)-induced ﬁbroblast migration, and inhibits DF differentiation into DM mediated by
NGF or TGF-β1. Finally, in DM, apremilast signiﬁcantly reduces cAMP degradation induced by treatment
with β-amyloid. Taken together, these results indicate that PDE4 play an important role in psoriasis. In ad-
dition, the study reveals that the PDE4/CD271 complex could be important in modulating ﬁbroblast
functions.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
PDE4
PBMC
Apremilast
Psoriasis
Myoﬁbroblasts
CD271ysis of variance; BSA, body surface area; cAMP, cyclic adenosine monophosphate; DAPI, 4′,6-diamidino-2-phenylindole
pus erythematosus; DM, dermal myoﬁbroblasts; DMSO, dimethyl sulfoxide; EGTA, ethylene glycol tetraacetic acid; ELISA,
-activated cell sorting; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating fac-
amma; IgM, immunoglobulin M; IHC, immunohistochemistry; IL1, interleukin 1; IP-10, IFN-ɣ-inducible protein 10 (C-X-Cmotif
opolysaccharide; MDC, macrophage-derived chemokine; MDC, macrophage-derived chemokine; MCP, monocyte chemotactic
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NGF, nerve growth factor; NR, not reported; NT, neurotrophin;
PASI, Psoriasis Area and Severity Index; PBMC, peripheral blood mononuclear cells; PDE, phosphodiesterase; PI, propidium io-
-PCR, reverse transcriptase-polymerase chain reaction; SEA, staphylococcal enterotoxin A; SEB, staphylococcal enterotoxin B;
ematosus; SMA, smoothmuscle actin; sPGA, static Physician Global Assessment; TA, transit amplifying; TBS, tris buffered saline;
ceptor 4; TNF-α, tumor necrosis factor-alpha; TRK, tyrosine kinase; TUNEL, terminal deoxynucleotidyl transferase (TdT)-medi-
beling; VEGF, vascular endothelial growth factor.
rris Avenue, Summit, NJ 07901, USA.
. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
754 P.H. Schafer et al. / Cellular Signalling 28 (2016) 753–7631. Introduction
cAMP is a pivotal second messenger that regulates inﬂammatory
responses [1]. cAMP is degraded through the activity of the large su-
perfamily of phosphodiesterases (PDE) [2]. Within this group, en-
zymes of the four-gene PDE4 family play a key role in degrading
cAMP in inﬂammatory cells, as well as endothelial cells, smooth
muscle cells, and keratinocytes [3]. There are also more than 20
splice variants encoded by the PDE4A, PDE4B, PDE4C, and PDE4D
genes, due to differential mRNA splicing genes [4]. PDE4 isoforms
display a differential expression pattern in human testis, skeletal
muscle, lung, and brain [5–7]. However, the expression patterns of
PDE4 isoforms have not been studied in blood or skin of patients
with inﬂammatory disease such as psoriasis.
PDE4 inhibitors are a well-characterized class of pharmaceutical
agents, with a broad range of anti-inﬂammatory activities in vitro, and
in in vivo preclinical models of asthma, lung neutrophilia, arthritis, in-
ﬂammatory bowel disease, multiple sclerosis, osteoporosis, and other
conditions [8–10]. Apremilast is a novel, orally administered, small mol-
ecule PDE4 inhibitor approved for treatment of psoriatic arthritis (PsA)
and moderate to severe plaque psoriasis [11,12]. By inhibiting PDE4,
apremilast elevates intracellular cAMP levels and thus down-regulates
the inﬂammatory response by modulating expression of a network of
pro- and anti-inﬂammatory mediators implicated in psoriasis and PsA
[13–15]. Selige et al. found different PDE4 subtypes with distinct func-
tions in human lung ﬁbroblasts and highlighted the predominant role
of PDE4B in controlling pathophysiological processes of human lung ﬁ-
broblasts. This provides a rationale for targeting of PDE4B to treat respi-
ratory diseases with ﬁbrotic lesions in the lung [16]. Schafer et al.
showed that apremilast does not inhibit proliferation in normal primary
human epidermal keratinocytes; however, apremilast inhibited tumor
necrosis factor-alpha (TNF-α) production by keratinocytes upon UVB
exposure (50 mJ/cm2) [17]. Sachs et al. found a new mechanism in
which PDE4A4/5 interacts with CD271 to enhance cAMP degradation.
The CD271-dependent down-regulation of cAMP results in a decrease
in extracellular proteolytic activity [18]. CD271 is a neurotrophin (NT)
receptor, also known as p75NTR, that belongs to the TNF receptor super-
family and shares with the other members of the family the death do-
main. The role of CD271 is complex: it may increase high-afﬁnity
binding of Trk receptors to NTs, and enhances the survival signal. By
contrast, CD271 alone can induce apoptosis upon speciﬁc binding,
such as with β-amyloid, via its own transduction pathway and by
interacting with a mounting number of downstream molecules [19].
Neurotrophins and their receptors have autocrine and paracrine func-
tions within the skin [20]. Moreover, our group has recently demon-
strated that CD271 is expressed by basal keratinocytes, speciﬁcally by
transit-amplifying (TA) cells [21]. It should be noted that the crosstalk
between the epidermal and dermal compartments is necessary to sus-
tain epidermal homeostasis, and that some factors that are produced
in the dermal compartment act on stem cells that reside in the epider-
mis. Moreover, Palazzo et al. showed that both dermal human ﬁbro-
blasts and myoﬁbroblasts express NT, CD271, and tyrosine kinase
(Trk) receptors, and that NTs exert a critical role in tissue remodeling
and wound healing [22].
In the current set of experiments, we report gene expression pat-
terns of PDE4 isoforms (A, B, C, and D) in peripheral blood mononu-
clear cells (PBMC) from healthy donors and from patients with a
variety of immune-mediated or inﬂammatory diseases including
psoriasis, as well as the effect of apremilast on cytokine and chemo-
kine production from PBMC of patients with psoriasis. We further re-
port immunohistochemistry studies showing the isoform
distribution of PDE4 in skin samples from healthy donors and pa-
tients with psoriasis, atopic dermatitis (AD), and discoid lupus ery-
thematosus (DLE). We then examine PDE4 isoform binding to
CD271 in ﬁbroblasts cultured from healthy skin, and analyze the
function of the PDE4/CD271 complex in ﬁbroblasts.2. Materials and methods
2.1. Gene Expression Analysis of PDE4 Isoforms in PBMC
Viably frozen PBMC and autologous serum from healthy volun-
teers or patients with psoriasis, rheumatoid arthritis (RA), idiopathic
pulmonary ﬁbrosis (IPF), sarcoidosis, scleroderma, Crohn's disease,
or systemic lupus erythematosus (SLE; n = 5 from each disease)
were purchased from Conversant Healthcare Systems (Huntsville,
AL). The diagnosis of disease was made on a case report form by
the responsible physician in a network of medical clinics, research
clinics, hospitals, and outpatient medical facilities. Peripheral blood
mononuclear cells were thawed and cultured in RPMI-1640 supple-
mented with 5% of each patient's autologous serum for 24 h
to allow cells to recover from freezing and thawing. Cells
(1 × 106 PBMC per patient) were collected for gene expression anal-
ysis by hybridization array. Cells were washed with cold phosphate-
buffered saline, lysed with 350 μL RLT buffer (Qiagen, Gaithersburg,
MD), and transferred to barcoded tubes. RNAwas extracted and con-
verted to cDNA using the Ovation Whole Blood Solution (NuGEN
Technologies, San Carlos, CA), and hybridized to HG-U133 Plus 2.0
arrays (Affymetrix, Santa Clara, CA). Gene expression data were nor-
malized and provided by Covance Genomics Laboratory (Seattle,
WA). Statistical comparison for PBMC from each disease versus nor-
mal control was by one-way analysis of variance. Affymetrix probes
were annotated using the GeneAnnot microarray gene annotation
database at the Weizmann Institute of Science (http://genecards.
weizmann.ac.il/geneannot/index.shtml) and identiﬁed in speciﬁc
gene splice variants using BLAST at National Center for Biotechnolo-
gy Information (NCBI) (http://blast.ncbi.nlm.nih.gov/Blast.cgi).2.2. Quantitative RT-PCR
Quantitative reverse transcriptase-polymerase chain reaction
(qRT-PCR) was performed to conﬁrm overexpression of PDE4B and
PDE4D isoforms in PBMC from patients with psoriasis. PBMC samples
(n = 20 each from psoriasis patients and healthy donors) were cul-
tured for 24 h in 5% autologous serum. RNA was isolated, converted
to cDNA, and analyzed by qRT-PCR, and a comparison of PBMC
from patients with psoriasis versus normal controls was conducted
by t test.2.3. Multiplexed bead-based immunoassay
Peripheral blood mononuclear cells from patients with psoriasis
(n = 10) were obtained after informed consent by Conversant
Healthcare Systems. The diagnosis of psoriasis was made on a case re-
port form by the responsible physician in a network of medical clinics,
research clinics, hospitals, and outpatient medical facilities. Peripheral
blood mononuclear cells were thawed (minimum viability was 80%),
plated at 2 × 105 cells/well, and stimulated in duplicate via various im-
mune receptors with or without apremilast (1 μM) in 0.1% dimethyl
sulfoxide (DMSO) for 24 h. Immune cell stimuli included 1 ng/mL lipo-
polysaccharide (LPS; Sigma, St. Louis, MO), targeting toll-like receptor 4
(TLR4) on monocytes, dendritic cells, and B cells; 10 ng/mL each of
staphylococcal enterotoxin A and B (Toxin Tech, Sarasota, FL), targeting
T-cell receptors; 2 ng/mL each of TNF-α+ interleukin (IL)-1β (Sigma),
targeting TNF and IL-1 receptors onmonocytes, dendritic cells, B cells, T
cells, and natural killer cells; and 2 μg/mL anti-immunoglobulinM (IgM;
Jackson ImmunoResearch, West Grove, PA), targeting B-cell receptors.
The production of 25 protein analytes was measured by cytometric
bead array using Milliplex MAP Human Cytokine/Chemokine beads
(EMD Millipore Corporation, Billerica, MA) on a MagPix instrument
(Luminex, Austin, TX).
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Immunohistochemistry (IHC) was performed on dermis samples
from healthy controls and from patients with psoriasis, AD, and DLE at
University of Modena and Reggio Emilia, Modena, Italy. Parafﬁn em-
bedded biopsies (4 μm) were stained for protein analysis by IHC as
follows: PDE4A, rabbit polyclonal antibody (1:100; Proteintech
Group, Chicago, IL); PDE4B, rabbit polyclonal antibody (1:40; Santa
Cruz Biotechnology); PDE4C, rabbit polyclonal (1:40; Santa Cruz Bio-
technology); PDE4D, rabbit polyclonal antibody (1:40; Santa Cruz
Biotechnology); and CD271, mouse monoclonal antibody (1:100;
Upstate, Lake Placid, NY). After washes, slides were incubated with
secondary antibody for 45 min at room temperature. Fast Red was
used as chromogen; stainings were performed according to the
UltraVision LP Detection System AP Polymer & Fast Red Chromogen
assay (Thermo Fisher Scientiﬁc, Waltham, MA). The expression in-
tensity was quantitatively determined using ImageJ software
(Wayne Rasband, National Institute of Mental Health, Bethesda,
MD). Detailed histopathology and immunohistochemistry of
PDE4A, PDE4B, and PDE4D protein expression in psoriatic skin was
performed by LifeSpan Biosciences, Inc. (Seattle, WA) using the pri-
mary antibodies as described above. The principal detection system
consisted of a Vector anti-rabbit secondary (BA-1000, Vector Labora-
tories, Peterborough, UK) and a Vector ABC-AP kit (AK-5000) with a
Vector Red substrate kit (SK-5100).2.5. Isolation of primary ﬁbroblasts and cell treatment
Normal human dermal ﬁbroblasts (DF) were isolated from healthy
skin biopsies obtained from waste materials from operating rooms. Pa-
tient consent for experiments was not required because Italian law con-
siders human tissue left over from surgery as discardedmaterial. Brieﬂy,
DF were obtained by explant culture and grown in Dulbecco's Modiﬁed
Eagle's Medium (DMEM) containing 5% fetal bovine serum (FBS).
Transforming growth factor-β1 (TGF-β1; 1 ng/mL; Sigma) was
added in ﬁbroblast secondary culture for 6 days to promote differen-
tiation into dermal myoﬁbroblasts (DM). The myoﬁbroblast pheno-
type was checked by immunostaining in situ of α-smooth muscle
actin (α-SMA).
For cell treatment, apremilast was diluted in DMSO 10mMand used
at the ﬁnal concentration of 10 μM in culture medium without serum.
Dermal ﬁbroblasts and MF were plated in DMEM with FBS. At 48 h
after seeding, apremilast or DMSO was added to DMEM for 2 h and,
after that, diluent, 100 ng/mL human recombinant nerve growth factor
(NGF; Sigma-Aldrich, St. Louis, MO), 1 ng/mL TGF-β1 (Sigma-Aldrich),
and 40 μM β-amyloid 25–35 (Bachem, Bubendorf, Switzerland) were
added to medium. Cells were monitored and used for further experi-
ments 48 h later.2.6. Immunoﬂuorescence in situ
Dermal ﬁbroblasts were plated on chamber slides and, 48 h after
seeding, were treated with TGF-β1 (1 ng/mL, Sigma-Aldrich) or diluent
alone. Six days later, cells were ﬁxed in situ in 4% paraformaldehyde for
20 min and air dried. After a rehydration in phosphate-buffered saline
(PBS), cells were permeabilized for 10 min with 0.5% Tryton X-100 in
0.1% sodiumcitrate, treated for 5minwith 50mMNH4Cl, and incubated
with 1% bovine albumin serum for 20 min. Then slides were incubated
for 1 h at room temperature with the mouse monoclonal anti-α-SMA
antibody (1:400; Sigma-Aldrich). Then cells were incubated with sec-
ondary antibody, Alexa Fluor 488 (1:100; Thermo Fisher Scientiﬁc). Fi-
nally, cell nuclei were stained with 1 μg/ml DAPI (Sigma-Aldrich).
Micrographs were taken on a Confocal Scanning Laser Microscopy
(Leica TCS SP2; Leica, Exton, PA).2.7. Co-immunoprecipitation
Dermal ﬁbroblasts and DMwere cultured until pre-conﬂuent condi-
tion. Cells were harvestedwith lysis buffer pH 7.5 (150 nMNaCl, 15mM
MgCl, 1 mM ethylene glycol tetraacetic acid [EGTA], 50 mMHepes, 10%
glycerol, 1% Triton) containing protease inhibitors. Monoclonal anti-
body CD271 (Upstate, Lake Placid, NY) was bound to Sepharose beads
for 1 h at 4 °C under rotation. Thereafter, precleared lysates were conju-
gated to Sepharose beads-antibody complex or, as control, to Sepharose
beads alone or to antibody alone, overnight at 4 °C under rotation.
Immunocomplexes were washed with binding buffer (50 mM Tris–
HCl, pH 7.5; 100 mM NaCl; 2 mM MgCl2, 1 mM DTT, 0.5% Triton X-
100, 0.5% bovine serum albumin) 6 times. Samples were eluted with
2× Laemmli sample buffer for 5 min at 90 °C and Western blotting for
PDE4A, B, C, and D was performed as described below.
2.8. Western blotting
Total proteins (20 μg) or immunocomplexes were analyzed under
non-reducing conditions on 7.5% polyacrylamide gels. To obtain total
proteins, cells were washed with PBS and lysed on ice, in lysis buffer
pH 7.5 (150 mM NaCl, 15 mM MgCl, 1 mM EGTA, 50 mM Hepes, 10%
glycerol, 1% Triton) containingprotease inhibitors. Brieﬂy, after the elec-
trophoretic separation, total proteins or immunocomplexes were blot-
ted onto nitrocellulose membranes. The blots were blocked for 2 h in
blocking buffer (PBS buffer, pH 7.4 with 0.2% Tween 20 and 5% nonfat
milk) and incubatedwith rabbit polyclonal anti-humanPDE4A antibody
(1:1000; Proteintech Group, Chicago, IL), rabbit polyclonal anti-human
PDE4B antibody (1:300; Santa Cruz Biotechnology), rabbit polyclonal
anti-human PDE4C antibody (1:300; Santa Cruz Biotechnology), rabbit
polyclonal anti-human PDE4D antibody (1:300; Santa Cruz Biotechnol-
ogy) or mouse monoclonal α-SMA (1:3000; Sigma-Aldrich) or mouse
monoclonal anti-β-actin (1:1000; Sigma) overnight at 4 °C. Thenmem-
branes were washed in TBS/Tween 20, incubated with peroxidase-
conjugated goat anti-mouse or goat anti-rabbit or anti-mouse
(1:3000; Bio-Rad, Hercules, CA) antibodies for 45 min at room temper-
ature. Finally, membranes were washed and developed using the ECL
chemiluminescent detection system (Amersham Biosciences UK Limit-
ed, Little Chalfont Buckinghamshire, UK). The band intensity was quan-
titatively determined using ImageJ software (Wayne Rasband, National
Institute of Mental Health, Bethesda, MD), and protein level intensity
was normalized to β-actin expression.
2.9. MTT Assay
Dermal ﬁbroblasts and DM were plated in a 96-well tissue culture
plate (5000 cells/well). At 48 h after plating, cells were treated as de-
scribed above with apremilast or DMSO for 2 h, then treated with dilu-
ent (control), NGF (100 ng/mL), neurotrophin-3 (NT3; 100 ng/mL), or
β-amyloid (40 μM). MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide) assay was performed 48 h later. Proliferative
cells were detected by incubating with MTT (Sigma-Aldrich) solution
at 37 °C for 4 h. The formazan dye produced after DMSO solubilization
was evaluated by a multiwall scanning spectrophotometer at 540 nm.
The results are expressed as viability percentage, as comparedwith con-
trol. Results are calculated as the mean ± SD of three different experi-
ments. Student's t test was performed for comparison of the means.
2.10. Propidium iodide Staining
At 48 h after cell seeding, DF and DMwere pretreated with DMSO or
apremilast as described above, then diluent (control) or 40 μM β-
amyloid was added. After 48 h, cells were trypsinized and resuspended
(5 × 105 cells) in 1 mL hypotonic ﬂuorochrome solution: 50 μg/mL
propidium iodide (PI) containing 0.1% sodium citrate and 0.5%
TrytonX-100 (Sigma). After 15 min, cells were analyzed using an Epics
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detected by evaluating the ﬂuorescence of hypodiploid cells counted in
subG1 region.
2.11. TUNEL assay
Dermal ﬁbroblasts andDMafter treatmentwere ﬁxed in situ in para-
formaldehyde (4% in PBS) and air-dried. The slides were stained with
the In Situ Cell Death Detection Kit (Roche Diagnostics, Basel,
Switzerland) as recommended by the manufacturer. Fluorescent speci-
mens were analyzed by confocal scanning laser microscopy (Leica TCSFig. 1. Gene expression analysis of PDE4 isoforms in PBMC from healthy volunteers or patients
samples (n= 5 for each immune/inﬂammatory condition)were cultured 24 h in 5% autologous
2.0 arrays. Representative results from one hybridization probe per gene are shown. *p b 0.05
psoriasis patients (N = 20 each) were cultured for 24 h in 5% autologous serum. RNA was
points. The boxes extend from the 25th to the 75th percentile, the whiskers represent the m
(p b 0.0001 versus normal controls, by t test).SP2, Leica Microsystems, Wetzlar, Germany) in conjunction with a con-
ventional opticalmicroscope (Leica DM IRBE, Leica). Resultswere calcu-
lated as the mean ± SD of three different experiments.
2.12. Migration assay
A total of 20 × 104 DFwere plated on 12-well tissue culture plates. At
48 h after seeding, cells were pretreated with DMSO or apremilast for
2 h as described above, then cells were treated with 5 μg/mLmitomycin
C for 1.5 h. Subsequently, the cells were washed three times in serum-
free medium and a line for each well was drawn along the cellwith psoriasis, RA, IPF, sarcoidosis, scleroderma, Crohn's disease, or SLE. (A, B, C, D) PBMC
serum. RNAwas isolated, converted to cDNA, and hybridized to Affymetrix HG-U133 Plus
versus normal controls by one-way ANOVA. (E) PBMC samples from healthy donors and
isolated, converted to cDNA, and analyzed by qRT-PCR. Dots represent individual data
inimum and maximum, and the lines in the middle of each box represent the median
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serum-free medium to remove all detached cells and incubated in me-
dium with 0.1% bovine serum albumin with 1 ng/mL TGF-β1,
100 ng/mLhuman recombinantNGF in presence of DMSOor apremilast.
Cells weremonitored at 24 and 48h from stimulation. The result of each
experimentwas expressed as themean ofmigrated cells from three dif-
ferent areas. The ﬁnal results are expressed as the mean ± SD of three
different experiments.
2.13. cAMP ELISA
At 48 h after cell seeding, DF and DMwere pretreated with DMSO or
apremilast as described above, then diluent, 100 ng/mL human recom-
binant NGF (Sigma-Aldrich), or 40 μM β-amyloid (Bachem) were
added to the culture medium.
48 h later, supernatants were collected, particulates were removed
by centrifugation and stored at −20 °C. cAMP quantitation was per-
formed by a competitive enzyme immunoassay (R&D Systems cAMP
immunoassay, R&D Systems, Minneapolis, MN) according to manufac-
turer instructions. The sample concentration was determined by absor-
bance at 540 nm against a standard curve. cAMP levels are given in
pmol/mL of cell lysate and results are expressed as mean± SEM of trip-
licate from three different experiments.
3. Results
3.1. Gene expression analysis of PDE4 Isoforms in PBMC
We ﬁrst wanted to analyze gene expression of PDE4 isoforms (A, B,
C, and D) in PBMC from healthy donors and from patients with 7 differ-
ent immune-mediated or inﬂammatory diseases: psoriasis, rheumatoid
arthritis (RA), idiopathic pulmonary ﬁbrosis (IPF), sarcoidosis, sclero-
derma, Crohn's disease, and SLE. PDE4B and PDE4D isoforms were in-
creased at the mRNA level in PBMC from psoriasis patients relative to
normal controls (Fig. 1B and D, p b 0.05). The PDE4B probe
(203708_at) corresponds with the National Center for Biotechnology
Information (NCBI) reference sequence NM_002600, found in PDE4B
variants A and D. The PDE4D probe (204491_at) corresponds with
NCBI reference sequence ID R40917, found in PDE4D variants 1 through
9. PDE4D was also increased versus normal controls in PBMC from pa-
tients with SLE (Fig. 1D, p b 0.05). PDE4C mRNA was preferentially
overexpressed in PBMC from patients with Crohn's disease versus nor-
mal controls (Fig. 1C), while PDE4A mRNA expression levels were sim-
ilar across PBMC from normal controls and patients with the various
immune/inﬂammatory diseases (Fig. 1A). The PDE4A probe (204,735-
at) corresponds with NCBI reference sequence ID NM_006202, found
in PDE4A variants 1 through 5, X1 and X3. The PDE4C probe
(206792_x_at) corresponds with NCBI reference sequence ID
NM_000923, found in PDE4C variants 1 through 4. To conﬁrm the over-
expression of PDE4B and PDE4DmRNA in PBMC frompatientswith pso-
riasis relative to normal controls, quantitative RT-PCR was performed
using 20 samples each from psoriasis patients and healthy donors.
Mean relative gene expression in PBMC from psoriasis patients was
5.4-fold higher for PDE4B, and 2.2-fold higher for PDE4D (p b 0.0001
for both versus normal control), compared with 1.1-fold for PDE4A
(p = NS) (Fig. 1E). There were no signiﬁcant correlations between
PDE4A, PDE4B, or PDE4D gene expression in the psoriatic PBMC with
PASI, BSA, or sPGA scores (data not shown).
3.2. Effect of apremilast on the production of inﬂammatory mediators by
PBMC from patients with psoriasis
Given the high PDE4 expression in psoriasis, we investigated the ef-
fect of apremilast on cytokines produced by PBMC from psoriatic pa-
tients. Psoriasis patient PBMC donors (n = 10) included 5 women and
5 men ranging in age from 26 to 42 years, with PASI scores ≤26 and≤33% body surface area affected. Two patients also had a diagnosis of
psoriatic arthritis. Changes in production of various cytokines and
chemokines upon stimulation of PBMCs from these psoriasis patients
with LPS, staphylococcal enterotoxin A and B, TNF-α/IL-1β, or anti-
IgM are shown in Fig. 2A. Addition of 1 μM apremilast had the greatest
effect on psoriatic PBMC cultures stimulated via TLR4 (i.e., LPS stimula-
tion), with 13 of the 25 analytes signiﬁcantly affected versus LPS control
(Fig. 2B). Speciﬁcally, apremilast caused signiﬁcant inhibition of LPS-
induced TNF-α, IL-12/IL-23p40, interferon gamma (IFN-γ), IP-10,
MCP-1, MCP-3, MIP-1β, IL-1α, IL-1β, and GM-CSF production, and in-
creased IL-10, G-CSF, and VEGF production. In psoriatic PBMC stimulat-
ed with anti-IgM to ligate the B-cell receptor, apremilast decreased
production of the cytokines TNF-α, IL-1α, and IFN-γ, and the
chemokines MCP-1, MCP-3, MIP-1β, and IP-10, and increased IL-10, G-
CSF, VEGF, and IL-6. In psoriatic PBMC cultures stimulated via the T-
cell receptor or TNF and IL-1 receptor, apremilast had far fewer effects
(data not shown).
3.3. PDE4 expression in inﬂammatory skin inﬁltrates
Psoriasis is an immune-mediated disease characterized by a dense
dermal inﬁltrate extravasating from the blood stream. Immuno-
inﬂammatory inﬁltrate in turn is responsible for the epidermal alter-
ations. For this reason, we focused on the expression of PDE4 proteins,
which are markedly elevated in PBMC from psoriatic patients, in the
dermal inﬁltrate from lesional psoriatic skin. Also, dermis from healthy
subjects, AD, and DLE was evaluated. In general, PDE4 staining was
higher in diseased versus normal skin when measured by ImageJ soft-
ware (Fig. 3A). PDE4A was expressed at the cytoplasmic level in a few
dermal cells, most likely ﬁbroblasts, in healthy skin, while it was mark-
edly increased in ﬁbroblasts from psoriasis, AD, and DLE. PDE4B was
slightly expressed by dermal cells both in healthy and psoriatic skin.
In AD, PDE4B staining was somewhat more expressed in the dermis of
AD skin compared with controls. In this context, dermal ﬁbroblasts ap-
peared intensely positive. In dermis from DLE skin, PDE4B staining was
markedly increased compared with healthy controls, DF being strongly
positive. PDE4C was considerably more expressed in the dermis from
psoriatic or AD sections than in skin from healthy controls. In DLE,
PDE4C staining intensity was higher than in AD or psoriasis, ﬁbroblasts
being intensely stained. PDE4D expression wasmarkedly higher in der-
mal inﬁltrate (ﬁbroblasts) from psoriasis, AD, or DLE than in healthy
skin. Finally, CD271 appeared more expressed in ﬁbroblasts from psori-
asis and AD than in healthy skin or DLE (Fig. 3B).
In order to better characterize PDE4 protein expression in psoriatic
skin, a more detailed analysis was performed in the dermis. PDE4A, B,
and D staining was evaluated and interpreted by a pathologist, and
each antibody was evaluated for the presence of speciﬁc signal and
level of background. Staining intensity was recorded on a 0–4 scale
(0 = negative, 1 = blush, 2 = faint, 3 = moderate, 4 = strong)
(Table 1). Overall, lymphocytes present in the psoriatic skin were mod-
erately to strongly positive for PDE4AandPDE4B, and faintly positive for
PDE4D. Pilosebaceous units, sweat glands, sweat ducts, hair follicles,
and arrector pili smooth muscle were positive. Fibroblasts were posi-
tive, and endothelium stained strongly for PDE4A, PDE4B, and PDE4D.
Speciﬁcally, PDE4A expression showed increased intensity and preva-
lence of staining in nearly all cell types in psoriatic versus normal sam-
ples, although neutrophils within microabscesses were exceptionally
negative. PDE4B staining in psoriatic samples was very prominent in
vessels in the superﬁcial dermis, and positively stained inﬂammatory
cells were more abundant than in normal samples. PDE4D staining in
psoriatic samples was present in ﬁbroblasts and endothelium. Lympho-
cytes frequently showed staining in both normal andpsoriatic skin sam-
ples, but were far more prevalent in the psoriasis samples. The
endothelium of psoriatic skin showed a relatively large increase in
PDE4 expression compared with normal skin, with PDE4A and PDE4D
displaying strong staining in psoriatic endothelium, but only faint
Fig. 2.Modulation of production of inﬂammatory cytokines and chemokines in psoriatic PBMC. (A) Production of 25 inﬂammatory cytokines and chemokines by psoriatic PBMC. Data are
the absolute means± SEM of 10 samples, each tested in duplicate, measured by cytometric bead array using Milliplex MAP Human Cytokine/Chemokine beads on a MagPix instrument.
(B) Effect of apremilast on LPS-stimulated PBMC from patients with psoriasis. Data are the means ± SEM percent relative to LPS control, from 10 psoriatic PBMC samples, each tested in
duplicate. *p b 0.05, **p b 0.01, ***p b 0.001 versus LPS control by two-way ANOVA, followed by Bonferroni post-test to compare replicate means.
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moderate to strong in psoriatic skin, but absent in normal skin. PDE4D
expression was moderate in psoriatic ﬁbroblasts, but faint in normalﬁbroblasts. In overall terms of staining intensity, the endothelium and
ﬁbroblasts showed the largest consistent increase in PDE4 expression
in psoriatic versus normal skin.
Fig. 3. PDE4/CD271 expression in healthy and pathologic dermis. (A) PDE4A, PDE4B, PDE4C, PDE4D isoforms and CD271 in dermis from healthy controls and patients with psoriasis, AD,
andDLEwere detected by IHC. Fast redwas used as chromogen. Bar (shown in top left image=200 μm) (B) The expression intensity of PDE4A, PDE4B, PDE4C, PDE4D isoforms andCD271
in (A) was quantitatively measured using ImageJ software as described in the Materials andMethods. Relative staining intensities are shown, normalized to intensities in healthy dermis
for each individual antibody.
759P.H. Schafer et al. / Cellular Signalling 28 (2016) 753–7633.4. PDE4 Isoforms Co-immunoprecipitate with CD271 in ﬁbroblasts
Due to the large increase in PDE4 staining observed in psoriatic ﬁ-
broblasts, this cell type was selected for functional studies to determine
the role of PDE4 in cellular responses. Different proinﬂammatory cyto-
kines, including TGF-β1, promote ﬁbroblast differentiation into
myoﬁbroblasts, characterized by the expression of α-SMA. These cells
are predominantly responsible for connective-tissue contracture and
extracellular matrix reorganization in different physiopathologic pro-
cesses in the skin, including wound healing and ﬁbrosis [23]. We
showed that all PDE4 isoforms are expressed in dermal ﬁbroblasts
(DF) and myoﬁbroblasts (DM) cultured from healthy donors at the
mRNA level (Fig. 4A, B, C), while PDE4 protein levels are higher in DM
than in DF (Fig. 4D). PDE4A had previously been found to associate
with CD271 to enhance cAMP degradation in ﬁbroblasts, and to regulateﬁbrotic responses [18]. Because CD271 is also expressed in skin ﬁbro-
blasts [22], we wanted to determine if PDE4 isoforms (PDE4A, B, C,
and D) co-localize with CD271 in dermal ﬁbroblasts. We showed that
PDE4 isoforms co-immunoprecipitate with CD271 in DM (Fig. 4E).
However, in DF, CD271 formed only weak complexes with PDE4A and
PDE4B and no complexes with PDE4C or PDE4D.
3.5. PDE4/CD271 complex function in ﬁbroblasts in Vitro
To evaluate the effect of the PDE4/CD271 complex on proliferation
and apoptosis in ﬁbroblasts, DF and DM were pretreated with
apremilast or DMSO for 2 h and then treated with NGF, NT3, β-
amyloid, or diluent. Treatment with β-amyloid signiﬁcantly decreased
the percentage of proliferative cells for both DF and DM cultures com-
pared with diluent control. In DM, the addition of apremilast
Table 1
Detailed summary of PDE4 IHC staining scores in normal and psoriatic skin. Sectionswere
stained with antibodies speciﬁc for PDE4A, B, or D and interpreted by a pathologist. Each
antibody was evaluated for the presence of speciﬁc signal and level of background. Stain-
ing intensity was recorded on a 0–4 scale (0 = negative, 1 = blush, 2 = faint, 3 =
moderate, 4 = strong). Data shown are the mean values determined by staining of skin
sections from 3 normal subjects and 3 psoriatic patients. NR =not reported.
PDE4 isozyme
Normal Psoriatic
A B D A B D
Squamous epithelium 4.0 NR 2.2 4.0 1.5 2.8
Arrector pili smooth muscle 3.3 2.0 2.5 NR 2.0 2.3
Sweat glands/ducts 3.3 2.0 2.3 4.0 2.0 2.5
Pilosebaceous units 2.8 2.0 2.0 4.0 2.0 NR
Vascular smooth muscle 2.5 2.0 2.0 4.0 2.0 NR
Endothelium 2.0 2.0 2.3 4.0 3.2 4.0
Inﬂammatory cells 2.5 3.0 2.5 4.0 2.5 2.3
Peripheral nerves 1.3 0.0 1.0 2.3 0.0 2.0
Adipocytes 0.5 0.5 1.3 0.0 0.0 0.0
Fibroblasts 0.0 1.0 2.0 3.5 1.0 3.0
760 P.H. Schafer et al. / Cellular Signalling 28 (2016) 753–763signiﬁcantly inhibited the effect of β-amyloid (p b 0.05 versus DMSO),
while apremilast had no effect versus DMSO in DF (Fig. 5A, B). Similarly,
the addition of apremilast signiﬁcantly reduced the induction of apopto-
sis by β-amyloid treatment in DM (p b 0.05 versus DMSO, Fig. 5D, F) but
not in DF (Fig. 5C, E).
It has been shown previously that neurotrophinsmediate DFmigra-
tion, and that neurotrophins aswell as TGF-β1 induce DF to differentiateFig. 4. PDE4/CD271 expression in ﬁbroblasts and myoﬁbroblasts in vitro. (A) α-SMA expressio
6 days by immunoﬂuorescence in situ. Cell nuclei were counterstained with DAPI (blue);
determined by Western blot analysis. Vinculin was used as a loading control. (C) Levels of
analysis. Bar graph shows the average densitometry values normalized to β-actin. (D) PDE4 i
used as a loading control. Bar graphs show the average densitometry values normalized to β-
CD271 antibody and immunoblotted with PDE4A, PDE4B, PDE4C, and PDE4D antibodies and winto DM by expressingα-SMA [22]. We therefore analyzed whether the
addition of apremilast could affect DFmigration andα-SMA expression.
Apremilast inhibited DF migration induced by both NGF and TGF-β1
treatment (Fig. 6A, B). Similarly, apremilast inhibited the up-
regulation of α-SMA expression induced by NGF and TGF-β1, especially
6 days after treatment (Fig. 6C).
cAMP ELISA was performed to evaluate whether activation of the
CD271/PDE4 complex leads to cAMP degradation. In this analysis, nei-
ther apremilast alone nor apremilast in combination with NGF exerted
any signiﬁcant effect on release of cAMP by either DF or DM (Fig. 7A).
On the other hand, in DM, Apremilast reduced cAMP degradation in-
duced by treatment with β-amyloid (Fig. 7B).
4. Discussion
In this series of experiments characterizing the role of PDE4 isoforms
in psoriasis, gene expression studies indicate that PDE4B and PDE4D
mRNA are overexpressed in PBMC from donor patients with psoriasis
relative to normal controls (healthy volunteers) or patients with other
inﬂammatory and immune-mediated diseases. Polymerase chain reac-
tion experiments conﬁrmed that, on average, the overexpression of
the PDE4B gene is 5.4-fold, and the overexpression of the PDE4D gene
is 2.2-fold, compared with normal PBMC. Regarding the effect of the
PDE4 inhibitor apremilast on cytokine/chemokine production of stimu-
lated PBMCs frompatientswith psoriasis, apremilast has the greatest ef-
fect on responses to TLR4 stimulation,with a similar pattern observed in
B-cell receptor-stimulated PBMC. Apremilast consistently decreasesn in DF and DM obtained after treatment with diluent (control) or TGF-β1 (1 ng/mL) for
bar = 20 μm. (B) After diluent (control) or TGF-β1 treatment, levels of α-SMA were
PDE4A, PDE4B, PDE4C, and PDE4D mRNA in DF and DM were determined by RT-PCR
soform expression in DF and DM was determined by Western blot analysis. β-Actin was
actin (fold-expression). (E) DF and DM protein extracts were immunoprecipitated with
ith PAS-only as control.
Fig. 5.Apremilastmodulation of apoptosis in DF or DM. DF or DM cultureswere pretreatedwith apremilast (10 μM) or DMSO for 2 h, then NGF (100 ng/mL), NT3 (100 ng/mL), β-amyloid
(40 μM), or diluent (control)were added.MTT assaywas performed 48 h after stimulation of DF (A) or DM(B). Results are represented as percentageswith respect to diluent. At 48 h after
the addition of stimuli, PI stainingwas performed and subG1peaks of DF (C) orDM(D)were analyzed by FACS analysis. TUNEL assaywasperformed and apoptotic nuclei of DF (E) andDM
(F) were counted. Data represent the means ± SE of triplicate determinations.
761P.H. Schafer et al. / Cellular Signalling 28 (2016) 753–763production of the cytokines TNF-α, IL-1α, and IFN-γ, and the
chemokines MCP-1, MCP-3, MIP-1β, and IP-10. In psoriatic PBMC cul-
tures stimulated via the T-cell receptor or TNF and IL-1 receptors,
apremilast has far fewer effects. On the other hand, apremilast induces
an up-regulation of IL-10 and G-CSF production under all conditions.
Because of the higher PDE4 gene expression observed in psoriasis
patient blood, an analysis of the skin was conducted. PDE4 proteinFig. 6. Effect of apremilast on DF migration and differentiation. DF cultures were pretreated w
diluent, NGF, or TGF-β1 were added to medium as described in Materials and Methods. Cell pi
means ± SE of triplicate determinations. (C) DF cultures were pretreated with apremilast or D
blot analysis was performed for α-SMA and β-actin was used as internal control. Bars show th
three times with similar results.expression is higher in the skin of patients with psoriasis, AD, and DLE
as comparedwith normal skin. In a detailed IHC analysis of PDE4protein
expression in psoriatic skin, the endothelium and ﬁbroblasts, in particu-
lar, show increased expression of PDE4A and PDE4D as compared with
normal skin. Little had previously been known about the expression of
PDE4 isoforms in human dermal ﬁbroblasts. Selige and colleagues
showed that primary normal human lung ﬁbroblasts (NHLF) expressith apremilast (10 μM) or DMSO for 2 h. After that, scratching assay was performed and
ctures were taken 48 h later (A) and migrating cells were counted (B) Data represent the
MSO for 2 h, after which diluent, NGF, or beta-amyloid were added to medium. Western
e densitometric analysis of α-SMA normalized to β-actin. The experiment was repeated
Fig. 7. cAMP degradation by PDE4/CD271 complex activation in DF and DM. DF and DMwere pretreated with apremilast (10 μM) or DMSO for 2 h, then NGF or β-amyloid were added to
medium as described inMaterials andMethods. Supernatants of DF (A) or DM(B)were collected 48 h later and cAMP levelswere evaluated by ELISA analysis. Data represent themeans±
SE of triplicate determinations.
762 P.H. Schafer et al. / Cellular Signalling 28 (2016) 753–763PDE4A, B, andD,while PDE4C is only barely detected [16]. In the present
study, we found that all PDE4 isoforms are expressed in both DF and
DM, even if at different levels. Regarding dermal compartment, all
PDE4 isoforms are expressed at the mRNA level both in DF and DM.
DM express higher levels of PDE4 isoform proteins than DF. DM invade
and repair injured tissues by secreting and organizing the extracellular
matrix and by developing contractile forces. At the endof the normal re-
pair process, DM disappear by apoptosis. In pathologic conditions, DM
likely remain, leading to excessive scarring [24]. Indeed, DM play an im-
portant role in organogenesis, oncogenesis, inﬂammation, repair, and ﬁ-
brosis in most organs and tissues [25]. We found that all four PDE4
proteins are up-regulated in cells of the dermal compartment in biop-
sies from inﬂammatory conditions. We postulate that these cells could
be DM, and suggest that PDE4 proteins play a role in the above-
mentionedDM functions, althoughmore functional studies are deﬁnite-
ly needed.
Because PDE4 isoforms are expressed in dermal ﬁbroblasts and evi-
dence has indicated an interaction between PDE4 and the CD271, which
may be important in tissue remodeling and wound healing [22], we
assessed the effect of PDE4 inhibition on the function of the PDE4/
CD271 complex in DF and DM. We ﬁrst showed all PDE4 isoforms co-
immunoprecipitate with CD271 in DM. Inhibition of PDE4 with
apremilast reduces cAMP degradation mediated by β-amyloid in DM,
as well as β-amyloid-mediated induction of apoptosis and reduction
of proliferative cells. Addition of apremilast also reduces DF migration
and differentiation mediated by NGF and TGF-β1. Taken together,
these results indicate that PDE4 play an important role in psoriasis. In
addition, the study reveals that the PDE4/CD271 complex could be im-
portant in modulating ﬁbroblast functions.Acknowledgments
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